Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives

15:

• A method for preventing or treating NSCLC (non-small cell lung cancer), comprising administering a therapeutically effective amount of a compound represented by the following Chemical Formula 1, an isomer thereof, and a pharmaceutically acceptable salt thereof to a subject in need thereof:
• wherein,
• R1 is substituted or unsubstituted C3-C10 aryl or substituted or unsubstituted C3-C10 heteroaryl with at least one nitrogen (N) atom;
• R3 is hydrogen, C1˜C6 alkyl, C2˜C6 alkenyl, C2˜C6 alkynyl, C3˜C6 aryl, C3˜C10 heteroaryl with at least one N atom, C3˜C10 arylalkyl or C3˜C10 heteroarylalkyl with at least one N atom;
• A is hydrogen or C1˜C6 alkyl;
• B is hydrogen or C1˜C6 alkyl;
• X is —O—PO3H2 or —OH;
• and
• Y is hydrogen, C3˜C10 aryl, C3˜C10 heteroaryl with at least one N atom or C1˜C6 alkyl.

17:

• The method of claim 15, wherein,
• R1 is naphthyl, quinolinyl, indolyl, substituted naphthyl, substituted quinolinyl or substituted indolyl,
• wherein the substituted naphthyl, the substituted quinolinyl and the substituted indolyl have at least one substituent selected from C1˜C6 alkyl,
• wherein Ra and Rb may be independently hydrogen, C1˜C6 alkyl, pyridinyl or amino-substituted pyridinyl and may be condensed together to form a ring;
• R3 is methyl or propenyl;
• either or both of A and B is hydrogen;
• X is —O—PO3H2 or —OH;
• and
• Y is hydrogen.

19:

• The method of claim 15, wherein,
• R1 is
• R3 is
• or methyl;
• either or both of A and B is hydrogen;
• X is —O—PO3H2 or —OH;
• and
• Y is hydrogen.

20:

• The method of claim 15, wherein the compound of Chemical Formula 1 is selected from the group consisting of the compound represented by one of the following Chemical Formulas 2 to 11, an isomer thereof, and a pharmaceutically acceptable salt thereof:
• No.
• Chemical Formula
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11

22:

• The method of claim 15, wherein the compound of Chemical Formula 1 is selected from the group consisting of the compound represented by one of the following Chemical Formulas 1-2 to 1-7, an isomer thereof, and a pharmaceutically acceptable salt thereof:
• No.
• Chemical Formula
• 1-2
• 1-3
• 1-4
• 1-5
• 1-6
• 1-7

23:

• The method of claim 15, wherein the compound of Chemical Formula 1 is selected from the group consisting of the compound represented by one of the following Chemical Formulas 2-1 to 2-8, an isomer thereof, and a pharmaceutically acceptable salt thereof:
• No.
• Chemical Formula
• 2-1
• 2-2
• 2-3
• 2-4
• 2-5
• 2-6
• 2-7
• 2-8